David Burt

Biography

Dr. David Burt is Director of R&D, North America for GSK Biologicals. He is based at GSK’s R&D facility in Laval, Quebec where he is responsible for a scientific staff of over 130, and the development of vaccines against various infectious diseases, cancers and Alzheimer disease. Prior to its acquisition by GSK, he was Vice-President, Research at ID Biomedical Corporation of Quebec. He was also Vice-President, Research for Intellivax International, an R&D company specializing in nasal delivery of vaccines that was subsequently acquired by ID Biomedical. Before joining Intellivax, Dr. Burt spent 8 years in vaccine R&D at Pasteur Merieux Connaught (now Sanofi-Pasteur) in Toronto where he held various positions within the Division of Research including Section Head, Immunology and Project Leader for Influenza Vaccines. Dr. Burt was previously a research scientist at the National Institute for Medical Research, London, England. He received his Ph.D. in Immunology from the University of Birmingham and a BSc. in Biological chemistry from the Essex University, UK. He has published more than 40 peer-reviewed scientific manuscripts and is co-inventor on 7 patent applications including a novel influenza vaccine that is given by nasal spray rather than by injection. David has received various awards for his contributions to scientific endeavor and his activity in the community including the ‘African Achievement Award in Science’ in 1997 and the Harry Jerome Award for Health Sciences in 2006. 

Research Interest

 Immunology, Vaccines